Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure BioSciences has high hopes for Phasex Corporation collaboration on UST tech

Pressure BioSciences revealed on Wednesday it was to collaborate with Phasex Corporation
Pressure BioSciences has high hopes for Phasex Corporation collaboration on UST tech
There is a rapidly expanding market for non-psychoactive extracts of cannabis plant material

Pressure BioSciences Inc (OTCMKTS:PBIO) is to collaborate with Phasex Corporation to combine its  exciting ultra shear technology (UST) with the latter's processing methods to develop water-soluble nanoemulsions.

These (nanoemulsions) are mixtures of two or more liquids, which could be used in various products, including  medical, pharmaceuticals, and nutraceuticals, and the companies hope to create a CBD-enriched plant oil.

As reported earlier this month, the UST technology was recently issued its first two patents in China.

"Following discussions with our colleagues at PBI, we believe the UST platform can be scaled to a cost-effective, commercially-viable level," Hans Schonemann, the president of Phasex, one of the world's most experienced supercritical fluid (SCF)-based toll processors.

"This would allow production of large quantities of stable, water-soluble nanoemulsions of compounds that were previously water-insoluble, such as CBD from cannabis.

"Such aqueous nanoemulsions could significantly increase the absorption and bioavailability of CBD and other previously water-insoluble compounds, which we believe would subsequently result in significant increases in their commercial demand."

Richard Schumacher, the chief executive and president at Pressure BioSciences, added: "We believe the ability to subject liquids to UST following the Phasex SCF extraction and purification process would be a highly sought-after "Value-add" for Phasex customers.

"Rapidly expanding markets for non-psychoactive extracts of cannabis plant material, for instance, is an example of a potentially high demand application for our combined, synergistic technologies.

"Oral bioavailability of CBD in aqueous emulsions has been previously demonstrated in several studies. Combining the capabilities and experience of PBI and Phasex could effectuate commercial scale production of such formulations with long shelf stability, which in turn could potentially result in a highly profitable service model for the PBI and Phasex collaboration."

UST is based on using intense shear forces generated from ultra-high pressure valve discharge - greater than 20,000 psi (pound per square inch).

Join our Crypto, Blockchain and Cannabis Telegram group here
View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

May 30 2018
The latest fundraiser underscores the fact the life sciences business is well supported in the City
July 31 2018
Life science generally is developing at an incredible speed, says Joe Anderson
Workers at CERN
August 02 2018
Private banks and healthcare groups took part in the share placing

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use